70
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

The impact of mild-to-moderate chronic kidney disease on hospitalization outcomes in patients with acute myeloid leukemia

ORCID Icon, , , &
Pages 1040-1044 | Received 26 Dec 2022, Accepted 06 Mar 2023, Published online: 20 Mar 2023
 

Disclosure statement

Kendra Sweet: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees for: Mablytics, AROG, Astellas, Curis, Pfizer, Bristol Myers Squibb, Syntrix Pharmaceuticals, Novartis, Gilead Inc, berGenBio.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.